

Gastrointestinal Malignancies - Colorectal Cancer

Saturday 24 September 2011, 11:15–13:50

19LBA

LATE BREAKING ABSTRACT

A Phase 2b, Double-Blind, Randomized Study Evaluating the Efficacy and Safety of Sorafenib (SOR) Compared With Placebo (PBO) When Administered in Combination With Chemotherapy (Modified FOLFOX6) for First-line Treatment (tx) of Patients (Pts) With Metastatic Colorectal Cancer (mCRC). The RESPECT Trial

J. Tabernero¹, R. Garcia-Carbonero², C.H. Köhne³, P.J. O'Dwyer⁴, A. Sobrero⁵, E. Van Cutsem⁶, O. Gladkov⁷, I. Davidenko⁸, R. Salazar⁹, J. Cassidy¹⁰. ¹Vall D'Hebrón University Hospital, Medical Oncology Department, Barcelona, Spain; ²Hospital Universitario Virgen del Rocio – Instituto de Biomedicina de Sevilla (IBIS), Medical Oncology Department, Sevilla, Spain; ³Klinikum Oldenburg, Medical Oncology Department, Oldenburg, Germany; ⁴Abramson Cancer Center, Hematology Oncology Department of Medicine, Philadelphia, USA; ⁵Oncologia Medica, Medical Oncology Department, Genova, Italy; ⁶University Hospital Gasthuisberg, Medical Oncology Department, Leuven, Belgium; ⁷Chelyabinsk Regional Clinical Oncology Center, Medical Oncology Department, Chelyabinsk, Russian Federation; ⁸Clinical Oncology Center #1, Medical Oncology Department, Krasnodar, Russian Federation; ⁹Instituto Catalán de Oncología, Medical Oncology Department, Barcelona, Spain; ¹⁰Beatson Laboratories, Medical Oncology Department, Glasgow, United Kingdom

Background: SOR, an oral multikinase inhibitor targeting angiogenesis and tumor growth, is indicated for renal and hepatic carcinomas. The RESPECT trial was an initial assessment of SOR in first-line mCRC in a randomized PBO-controlled setting.

Methods: Pts with mCRC and no prior therapy were randomized to SOR 400 mg or PBO twice daily with mFOLFOX6. Pts received mFOLFOX6 every 14 days. The primary endpoint was progression-free survival (PFS); secondary endpoints were overall survival (OS), time to progression (TTP), overall response rate (ORR), disease control rate (DCR), and duration of response (DOR). (ClinicalTrials.gov: NCT00865709. Sponsors: Bayer Healthcare and Onyx Pharmaceuticals)

Results: 198 pts were randomized: SOR arm (N = 97), PBO arm (N = 101). Baseline factors were balanced between SOR and PBO arms, except for gender (female, 57% v 38%) and KRAS status (wild type, 43% v 41%; mutant, 34% v 43%). To date, KRAS status has not yet been determined for ~20% of patients. There was no statistical difference between SOR and PBO arms for PFS (median, 9.1 v 8.7 mo; HR = 0.88, 95% CI 0.64–1.23; P = 0.23) or TTP (9.2 v 9.0 mo; HR = 0.83, 95% CI 0.59–1.17; P = 0.14). OS data are pending. ORR was 46% and 60% and DCR was 95% and 93% in the SOR and PBO arms, respectively. Exploratory subgroup analysis of PFS (SOR v PBO) by KRAS status showed a median of 9.6 v 9.2 mo for wild type (HR = 0.79; 95% CI 0.47–1.30) and 8.9 v 7.6 mo for mutant (HR = 0.89; 95% CI 0.53–1.51). The most common Grade 3/4 adverse events (AEs) in the SOR and PBO arms were neutropenia (48% v 22%), peripheral sensory neuropathy (6% v 12%), and Grade 3 hand-foot skin reaction (20% v 0%). Discontinuation of study treatment due to AEs was 9% in the SOR and 6% in the PBO arm.

Conclusions: The addition of SOR to first-line mFOLFOX6 in mCRC pts did not lead to a statistically significant improvement in PFS in unselected patients although a potential trend was suggested. A prespecified analysis of the KRAS mutant subgroup showed potential benefit of SOR, although the sample size was small. Safety data were consistent with SOR and mFOLFOX6 profiles with increased rates of some AEs.

Genitourinary Malignancies – Prostate Cancer

Sunday 25 September 2011, 09:00–11:00

20LBA

LATE BREAKING ABSTRACT

Celecoxib Plus Hormone Therapy Vs Hormone Therapy Alone for Hormone-sensitive Prostate Cancer: First Results From the STAMPEDE Randomised Controlled Trial (MRC PR08)

N.D. James¹, M.R. Sydes², M.D. Mason³, N.W. Clarke⁴, D.P. Dearnaley⁵, J. Dwyer⁶, G. Jovic², J.M. Russell⁷, G. Thalmann⁸, M.K.B. Parmar², on behalf of the STAMPEDE Investigators. ¹Queen Elizabeth Medical Centre, Birmingham, United Kingdom; ²MRC Clinical Trials Unit, Cancer Group, London, United Kingdom; ³Cardiff University School of Medicine, Cardiff, United Kingdom; ⁴Cardiff University School of Medicine, Christie and Salford Royal Foundation Trusts, Manchester, United Kingdom; ⁵Institute of Cancer Research and Royal Marsden Hospitals, Sutton, United Kingdom; ⁶Stockport, United Kingdom; ⁷Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; ⁸Inselpital Bern, Dept of Urology, Bern, Switzerland

Background: Long-term hormone therapy (HT) alone is the standard of care for men with metastatic or high-risk non-metastatic prostate cancer (PCa). The STAMPEDE trial is investigating whether early use

of additional therapies can improve overall survival. STAMPEDE is an international randomised controlled trial (NCT00268476), sponsored by the UK Medical Research Council. It uses novel multi-arm, multi-stage methods to assess the addition of 1 or 2 of three agents (docetaxel, zoledronic acid, celecoxib) in 5 research arms in men with PCa starting long-term HT for the first time.

Materials and Methods: HT was given as per standard care. Celecoxib was planned as 400 mg *bid* until the sooner of 1 year or disease (including PSA) progression. The trial has 3 intermediate activity stages (I–III) where the outcome measure (OM) is failure-free survival (FFS) and one final efficacy stage (IV) with overall survival as primary OM. At the end of each stage, research arms are compared pairwise to the control arm. Accrual of further patients is discontinued early for any research arm either showing (a) safety concerns or (b) insufficient evidence of activity (lack-of-benefit) where the treatment effect on FFS is compared against a pre-defined stopping guideline. The interim activity “hurdle” becomes increasingly stringent stage-by-stage, with the hazard ratio (HR) used when the hazards are proportional and restricted-mean survival time when they are not.

Results: From October 2008 to February 2011, 2,114 patients were consented and randomised, including 875 in this comparison. With 305 FFS events, there was no evidence of an advantage to HT+celecoxib over HT-alone: HR 0.98 (95% CI 0.90–1.06). The Independent Data Monitoring Committee recommended stopping accrual to this arm; stopping celecoxib was also recommended for patients currently on treatment. There was no evidence of differences in toxicity: 25% and 23% of patients reporting grade ≥3 toxicities or adverse events with or without celecoxib. Control arm FFS was 51% at 2 years, in line with expectations.

Conclusions: Celecoxib shows no evidence of activity in this setting. Accrual continues seamlessly to the other research arms. Follow-up of all arms is ongoing.

Support: The trial is supported by the MRC, CRUK, Novartis, Sanofi-Aventis and Pfizer

Genitourinary Malignancies – Prostate Cancer

Sunday 25 September 2011, 09:00–11:00

21LBA

LATE BREAKING ABSTRACT

Escalated-dose Conformal Radiotherapy for Localised Prostate Cancer: Long-term Overall Survival Results From the MRC RT01 Randomised Controlled Trial

D.P. Dearnaley¹, G. Jovic², I. Syndikus³, J.D. Graham⁴, E.G. Aird⁵, V. Khoo⁶, R. Cowan⁷, M.R. Sydes², on behalf of the RT01 Investigators. ¹Institute of Cancer Research and Royal Marsden Hospitals, Sutton, United Kingdom; ²MRC Clinical Trials Unit, Cancer Group, London, United Kingdom; ³Clatterbridge Centre for Oncology, Wirral, United Kingdom; ⁴Taunton & Somerset Hospital, Taunton, United Kingdom; ⁵Mount Vernon Hospital, Dept of Physics, Northwood, United Kingdom; ⁶Royal Marsden Hospital, London, United Kingdom; ⁷Christie Hospital, Manchester, United Kingdom

Background: Radiotherapy (RT) is one standard of care for men with localised prostate cancer (PCa). Conformal radiotherapy (CFRT) can deliver higher doses of radiation than standard-dose conventional radical external-beam radiotherapy and could improve long-term efficacy, potentially with increased toxicity.

Materials and Methods: Between Jan-1998 and Dec-2002, 862 consenting men with histologically confirmed T1b–T3a, N0, M0 PCa with PSA < 50 ng/mL, WHO performance status 0–1, normal blood counts and no previous PCa treatment joined RT01 (ISRCTN47772397). N = 843 were eligible to be randomised to standard-dose CFRT (Std: 64 Gy/32f; n = 421) or escalated-dose CFRT (Esc: 74 Gy/37f; n = 422). Randomisation was stratified on hospital and risk for seminal vesicle (SV) involvement (T-category, PSA, Gleason score). All received neo-adjuvant hormone therapy (HT) for 3 to 6 months pre-RT until the end of RT. The main efficacy outcome measures were biochemical progression-free survival (bPFS; time from randomisation until the first of: biochemical progression, re-start of HT, local progression, lymph node involvement, bone or other metastases or prostate-cancer death) and overall survival (OS; time from randomisation to death). Standard survival analysis methods were used. First activity results published in 2007 with ~5 years median follow-up showed an advantage to escalated-dose CFRT in terms of bPFS and some evidence of an advantage in metastases-free survival.

Results: At entry, median age was 67 yr; two thirds were at moderate risk for SV involvement, one third low risk. With median follow-up of 10 years, 239 deaths were reported (120 Std, 119 Esc). OS at 10 yr was 70% (95% CI = 65–75%) in each arm: hazard ratio (HR) from an adjusted Cox model 0.99 (95% CI = 0.77–1.28; p = 0.942). The assumption of proportional hazards was met (p = 0.337). 396 bPFS events were observed (224 Std, 172 Esc) and the previously observed advantage in bPFS was maintained: HR = 0.688 (95% CI = 0.56–0.84; p < 0.0001) in